T Cell-based Hepatitis C Vaccines
New Perspectives for T Cell-based Hepatitis C Vaccines Are the Focus of Review
Vaccine Weekly - Aug. 30, 2006
Aug. 30, 2006--(NewsRx.com) -- A researcher reviews new perspectives for T-cell-based hepatitis C vaccines in a recent issue of the Journal of Hepatology.
According to the review, "Three percent of the world's population is chronically infected with the hepatitis C virus (HCV) and at risk of developing liver cancer. Effective cellular immune responses are deemed essential for spontaneous resolution of acute hepatitis C and long-term protection. Here, we describe a new T-cell HCV genetic vaccine capable of protecting chimpanzees from acute hepatitis induced by challenge with heterologous virus."
"Suppression of acute viremia in vaccinated chimpanzees occurred as a result of massive expansion of peripheral and intrahepatic HCV-specific CD8+ T lymphocytes that cross-reacted with vaccine and virus epitopes," said Carlo Ferrari at the University of Parma.
"These findings show that it is possible to elicit effective immunity against heterologous HCV strains by stimulating only the cellular arm of the immune system, and suggest a path for new immunotherapy against highly variable human pathogens like HCV, HIV, or malaria, which can evade humoral responses," stated the author.
Ferrari published the review in the Journal of Hepatology (New perspectives for T-cell-based HCV vaccines. J Hepatol, 2006;45(1):163-165).
For more information, contact Carlo Ferrari, Division of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, I-43100 Parma, Italy. E-mail: cafer@tin.it.
Publisher contact information for the Journal of Hepatology is: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, The Netherlands.
Keywords: Parma, Italy, Hepatitis C Vaccine, Vaccine Development, Vaccine Efficacy, Hepatitis C Virus, Hepatology, Immunology, Immunotherapy, Liver Cancer Vaccine, Oncology, Virology.
Vaccine Weekly - Aug. 30, 2006
Aug. 30, 2006--(NewsRx.com) -- A researcher reviews new perspectives for T-cell-based hepatitis C vaccines in a recent issue of the Journal of Hepatology.
According to the review, "Three percent of the world's population is chronically infected with the hepatitis C virus (HCV) and at risk of developing liver cancer. Effective cellular immune responses are deemed essential for spontaneous resolution of acute hepatitis C and long-term protection. Here, we describe a new T-cell HCV genetic vaccine capable of protecting chimpanzees from acute hepatitis induced by challenge with heterologous virus."
"Suppression of acute viremia in vaccinated chimpanzees occurred as a result of massive expansion of peripheral and intrahepatic HCV-specific CD8+ T lymphocytes that cross-reacted with vaccine and virus epitopes," said Carlo Ferrari at the University of Parma.
"These findings show that it is possible to elicit effective immunity against heterologous HCV strains by stimulating only the cellular arm of the immune system, and suggest a path for new immunotherapy against highly variable human pathogens like HCV, HIV, or malaria, which can evade humoral responses," stated the author.
Ferrari published the review in the Journal of Hepatology (New perspectives for T-cell-based HCV vaccines. J Hepatol, 2006;45(1):163-165).
For more information, contact Carlo Ferrari, Division of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, I-43100 Parma, Italy. E-mail: cafer@tin.it.
Publisher contact information for the Journal of Hepatology is: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, The Netherlands.
Keywords: Parma, Italy, Hepatitis C Vaccine, Vaccine Development, Vaccine Efficacy, Hepatitis C Virus, Hepatology, Immunology, Immunotherapy, Liver Cancer Vaccine, Oncology, Virology.
0 comments:
Post a Comment